Vorapaxar Woes Increase Pressure On Remainder Of Merck CV Pipeline

The mid-January announcement that Merck & Co. was ending one pivotal trial and removing patients with a history of stroke from another for Phase III anti-clotting agent vorapaxar has called into question the pharma’s continued heavy emphasis on cardiovascular research and development.